Evidence map›Paper›PMID 24018833›Full record

ArticleBiotechnology and bioengineering2014

Multiwell stiffness assay for the study of cell responsiveness to cytotoxic drugs.

Silviya Zustiak, Ralph Nossal, Dan L Sackett

Open access · greenAbstract read
In one paragraph

Article in Biotechnology and bioengineering, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.

0numbers the graph read from it
0cells of the map it votes in
35citing papers in PubMed
3.1field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

35 citing papers in PubMed, 79 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Review
  10. Article
  11. Review
  12. Review
  13. Review
  14. Article
  15. Article
  16. Article
  17. Review
  18. Applicability of drug response metrics for cancer studies using biomaterials.Philosophical transactions of the Royal Society of London. Series B, Biological sciences · 2019
    Article
  19. Article
  20. Engineering Approaches to Study Cellular Decision Making.Annual review of biomedical engineering · 2018
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Silviya ZustiakProgram on Physical Biology (PPB), Eunice Kennedy Shriver National Institute of Child Health & Human Development, National Institutes of Health, 9000 Rockville Pike, Bldg. 9, Bethesda, Maryland, 20892. szustiak@slu.edu.
Ralph Nossal
Dan L Sackett
Eunice Kennedy Shriver National Institute of Child Health and Human Development · USNational Institutes of Health · US

Funding

Intramural NIH HHS Z99 HD999999
6 · The paper itself

Abstract

It is now well understood that the cell microenvironment, including the surrounding matrix, profoundly affects cell fate. This is especially true for solid tumors where, for example, matrix stiffness is believed to be an important factor in tumorogenesis. Our hypothesis is that since matrix stiffness affects cell fate, it may also be important in drug resistance. To test this hypothesis, we designed and built a multiwell polyacrylamide (PA) gel-based stiffness assay, in which the gels were coated with collagen in order to facilitate cell attachment and proliferation. This PA-based assay was used to examine the effect of stiffness on cultured cell responsiveness to cytotoxic drugs. In particular, we tested multiple cancer cell lines and their susceptibility to paclitaxel, a microtubule-targeting agent. By assessing cell proliferation, morphology, and the IC50 of the drug, we were able to establish that the stiffness affects responsiveness to cytotoxic drugs in a cell-dependent manner.

Indexed as

Chemical PhenomenaHydrogel, Polyethylene Glycol DimethacrylateAcrylic ResinsAntineoplastic AgentsCell Line, TumorCellsExtracellular MatrixHumansInhibitory Concentration 50PolyacrylamidesAcrylic ResinsAntineoplastic AgentsHydrogel, Polyethylene Glycol DimethacrylatePolyacrylamidescancerdrug resistancepaclitaxel (Taxol®)polyacrylamidesubstrate stiffness

Identifiers

PMID24018833
PMCPMC3933463
OpenAlexW2118739155

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.